Australia's Emyria hits 2-week high on launch of cannabis medicine
24/04/2023 02:44
** Shares of Emyria Ltd EMD.AX jump as much as 8.8% to
A$0.185, their highest since April 11
** The healthcare company says it introduced its proprietary
cannabinoid medicine pipeline, EMD-RX9
** Co says targeting FDA registration pathways comprising
FDA Pre-IND (Investigational New Drug) preparations and
head-to-head Phase 1 clinical trials with Epidyolex, planned for
second half of 2023
(Reporting by Poonam Behura in Bengaluru)
((Poonam.Behura@thomsonreuters.com;))